The LUNGevity Foundation calls for applications for the 2022 Pierre Massion Young Researcher Prize for research in early detection

A new awards program honors the late Dr. Massion, an internationally recognized expert in the field of early detection and prevention strategies for lung cancer; applications are now available online

WASHINGTON, January 27, 2022 /PRNewswire/ — The LUNGevity Foundation, the nation’s leading nonprofit organization focused on lung cancer, has issued a call for applications (RFA) for a new award, the Pierre Massion Young Investigator Award for Research on early detection. The RFA for this 2022 award is available on the LUNGevity website at and the ProposalCENTRAL website at

LUNGevity Foundation Logo (PRNewsfoto/LUNGevity Foundation)

The Pierre Massion Young Investigator Prize for research in early detection was created in memory of Pierre MassonMD, died in April 2021. Dr. Massion served on the Scientific Advisory Board of LUNGevity and was one of its founding members. He was Director of the Cancer Early Detection and Prevention Initiative and Co-Lead of the Cancer Health Outcomes and Control Research Program at Vanderbilt-Ingram Cancer Center, in addition to his tenure as Professor and other management positions Vanderbilt. This award program combines her passions for mentoring young researchers in early detection research and for eradicating health disparities.

LUNGevity’s Pierre Massion Young Investigator Early Detection Research Program was created to support underrepresented young faculty in the field of lung cancer early detection research. Research projects must demonstrate the translational relevance of the proposed research.

If selected, Massion Award recipients may receive a maximum of $100,000 for a one-year research project.

“This award is deeply meaningful to those who have had the opportunity to know Pierre, either as a colleague or as a physician,” said Charles Roudin, MD, PhD, Professor, Chief of Thoracic Oncology at Memorial Sloan Kettering Cancer Center and Chair of the Scientific Advisory Board of LUNGevity. “To continue his work in the field of early detection is a deserved tribute to his dedication, expertise, leadership and tireless optimism.”

To be eligible, applicants must be within the first five years of their initial faculty appointment. The Massion Awards are framed awards and a mentorship plan is part of the required submission.

Since 2002, scientific research projects funded by LUNGevity have totaled more than $24 millionrepresenting an investment in 149 projects at 61 facilities in 23 states.

Letters of Intent for the Pierre Massion Early Detection Young Investigator Fellowship should be submitted by February 23, 2022.

About the LUNGevity Foundation

LUNGevity Foundation is the leading national lung cancer organization focused on improving outcomes for people with lung cancer through research, education, policy initiatives, and support and engagement patients, survivors and caregivers. LUNGevity seeks to have an immediate impact on the quality of life and survival of all people affected by the disease, while promoting health equity by addressing disparities along the continuum of care. LUNGevity works tirelessly to advance research into early detection and more effective treatments, provide information and educational tools to empower patients and their caregivers, promote impactful public policy initiatives, and amplify patient voices through research. and commitment. The organization provides an active community for patients and survivors – and those who help them live longer and better.

Comprehensive resources include a medical and patient-centered review websitea toll-free number HELP line for the support, International Conference on Lung Cancer Survivorshipand an easy to use tool Search for clinical trials, among other tools. All of these programs aim to achieve our vision: a world where no one dies from lung cancer. The LUNGevity Foundation is proud to be a four-star establishment Charity Navigator organization.

Please visit to learn more.

About Lung Cancer in the United States

  • About 1 in 16 Americans will be diagnosed with lung cancer in their lifetime

  • More than 235,000 people in the United States will be diagnosed with lung cancer this year

  • About 65% of all new lung cancer diagnoses are in people who have never smoked or are former smokers

  • Lung cancer kills more than the next two deadliest cancers (colorectal and pancreatic) combined

  • Only 22% of all people diagnosed with lung cancer will survive 5 years or more, BUT if caught before it spreads, the chances of 5-year survival improve dramatically



See original content to download multimedia: -early-detection-research-301470181.html

SOURCE LUNGevity Foundation

Comments are closed.